Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK

<p><strong>Background:</strong>&nbsp;Some autoimmune diseases are associated with an increased risk of cardiovascular disease. We aimed to determine whether or not this is true, and to what extent, for a broad range of autoimmune conditions.</p> <p><strong>Met...

Olles dieđut

Bibliográfalaš dieđut
Váldodahkkit: Conrad, N, Verbeke, G, Molenberghs, G, Goetschalckx, L, Callender, T, Cambridge, G, Mason, JC, Rahimi, K, McMurray, JJV, Verbakel, JY
Materiálatiipa: Journal article
Giella:English
Almmustuhtton: Elsevier 2022
_version_ 1826309381375918080
author Conrad, N
Verbeke, G
Molenberghs, G
Goetschalckx, L
Callender, T
Cambridge, G
Mason, JC
Rahimi, K
McMurray, JJV
Verbakel, JY
author_facet Conrad, N
Verbeke, G
Molenberghs, G
Goetschalckx, L
Callender, T
Cambridge, G
Mason, JC
Rahimi, K
McMurray, JJV
Verbakel, JY
author_sort Conrad, N
collection OXFORD
description <p><strong>Background:</strong>&nbsp;Some autoimmune diseases are associated with an increased risk of cardiovascular disease. We aimed to determine whether or not this is true, and to what extent, for a broad range of autoimmune conditions.</p> <p><strong>Methods:</strong>&nbsp;In this population-based study, we used linked primary and secondary care records from the Clinical Practice Research Datalink (CPRD), GOLD and Aurum datasets, to assemble a cohort of individuals across the UK who were newly diagnosed with any of 19 autoimmune diseases between Jan 1, 2000, and Dec 31, 2017, younger than 80 years at diagnosis, and free of cardiovascular diseases up to 12 months after diagnosis. We also assembled a matched cohort with up to five individuals matched on age, sex, socioeconomic status, region, and calendar year, who were free of autoimmune disease and free of cardiovascular diseases up to 12 months after study entry. Both cohorts were followed up until June 30, 2019. We investigated the incidence of 12 cardiovascular outcomes and used Cox proportional hazards models to examine differences in patients with and without autoimmune diseases.</p> <p><strong>Findings:</strong>&nbsp;Of 22 009 375 individuals identified from the CPRD databases, we identified 446 449 eligible individuals with autoimmune diseases and 2 102 830 matched controls. In the autoimmune cohort, mean age at diagnosis was 46&middot;2 years (SD 19&middot;8), and 271 410 (60&middot;8%) were women and 175 039 (39&middot;2%) were men. 68 413 (15&middot;3%) people with and 231 410 (11&middot;0%) without autoimmune diseases developed incident cardiovascular disease during a median of 6&middot;2 years (IQR 2&middot;7&ndash;10&middot;8) of follow-up. The incidence rate of cardiovascular disease was 23&middot;3 events per 1000 patient-years among patients with autoimmune disease and 15&middot;0 events per 1000 patient-years among those without an autoimmune disease (hazard ratio [HR] 1&middot;56 [95% CI 1&middot;52&ndash;1&middot;59]). An increased risk of cardiovascular disease with autoimmune disease was seen for every individual cardiovascular disease and increased progressively with the number of autoimmune diseases present (one disease: HR 1&middot;41 [95% CI 1&middot;37&ndash;1&middot;45]; two diseases: 2&middot;63 [2&middot;49&ndash;2&middot;78]); three or more diseases: 3&middot;79 [3&middot;36&ndash;4&middot;27]), and in younger age groups (age &lt;45 years: 2&middot;33 [2&middot;16&ndash;2&middot;51]; 55&ndash;64 years: 1&middot;76 [1&middot;67&ndash;1&middot;85]; &ge;75 years: 1&middot;30 [1&middot;24&ndash;1&middot;36]). Among autoimmune diseases, systemic sclerosis (3&middot;59 [2&middot;81&ndash;4&middot;59]), Addison's disease (2&middot;83 [1&middot;96&ndash;4&middot;09]), systemic lupus erythematosus (2&middot;82 [2&middot;38&ndash;3&middot;33]), and type 1 diabetes (2&middot;36 [2&middot;21&ndash;2&middot;52]) had the highest overall cardiovascular risk.</p> <p><strong>Interpretation:</strong>&nbsp;These findings warrant targeted cardiovascular prevention measures, in particular in younger patients with autoimmune diseases, and further research into pathophysiological mechanisms underlying these complications.</p> <p><strong>Funding:</strong>&nbsp;Horizon 2020 Marie Skłodowska-Curie Actions and European Society of Cardiology.</p>
first_indexed 2024-03-07T07:34:51Z
format Journal article
id oxford-uuid:65bee19c-5217-4557-a196-845bf808f334
institution University of Oxford
language English
last_indexed 2024-03-07T07:34:51Z
publishDate 2022
publisher Elsevier
record_format dspace
spelling oxford-uuid:65bee19c-5217-4557-a196-845bf808f3342023-02-27T10:25:33ZAutoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UKJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:65bee19c-5217-4557-a196-845bf808f334EnglishSymplectic ElementsElsevier2022Conrad, NVerbeke, GMolenberghs, GGoetschalckx, LCallender, TCambridge, GMason, JCRahimi, KMcMurray, JJVVerbakel, JY<p><strong>Background:</strong>&nbsp;Some autoimmune diseases are associated with an increased risk of cardiovascular disease. We aimed to determine whether or not this is true, and to what extent, for a broad range of autoimmune conditions.</p> <p><strong>Methods:</strong>&nbsp;In this population-based study, we used linked primary and secondary care records from the Clinical Practice Research Datalink (CPRD), GOLD and Aurum datasets, to assemble a cohort of individuals across the UK who were newly diagnosed with any of 19 autoimmune diseases between Jan 1, 2000, and Dec 31, 2017, younger than 80 years at diagnosis, and free of cardiovascular diseases up to 12 months after diagnosis. We also assembled a matched cohort with up to five individuals matched on age, sex, socioeconomic status, region, and calendar year, who were free of autoimmune disease and free of cardiovascular diseases up to 12 months after study entry. Both cohorts were followed up until June 30, 2019. We investigated the incidence of 12 cardiovascular outcomes and used Cox proportional hazards models to examine differences in patients with and without autoimmune diseases.</p> <p><strong>Findings:</strong>&nbsp;Of 22 009 375 individuals identified from the CPRD databases, we identified 446 449 eligible individuals with autoimmune diseases and 2 102 830 matched controls. In the autoimmune cohort, mean age at diagnosis was 46&middot;2 years (SD 19&middot;8), and 271 410 (60&middot;8%) were women and 175 039 (39&middot;2%) were men. 68 413 (15&middot;3%) people with and 231 410 (11&middot;0%) without autoimmune diseases developed incident cardiovascular disease during a median of 6&middot;2 years (IQR 2&middot;7&ndash;10&middot;8) of follow-up. The incidence rate of cardiovascular disease was 23&middot;3 events per 1000 patient-years among patients with autoimmune disease and 15&middot;0 events per 1000 patient-years among those without an autoimmune disease (hazard ratio [HR] 1&middot;56 [95% CI 1&middot;52&ndash;1&middot;59]). An increased risk of cardiovascular disease with autoimmune disease was seen for every individual cardiovascular disease and increased progressively with the number of autoimmune diseases present (one disease: HR 1&middot;41 [95% CI 1&middot;37&ndash;1&middot;45]; two diseases: 2&middot;63 [2&middot;49&ndash;2&middot;78]); three or more diseases: 3&middot;79 [3&middot;36&ndash;4&middot;27]), and in younger age groups (age &lt;45 years: 2&middot;33 [2&middot;16&ndash;2&middot;51]; 55&ndash;64 years: 1&middot;76 [1&middot;67&ndash;1&middot;85]; &ge;75 years: 1&middot;30 [1&middot;24&ndash;1&middot;36]). Among autoimmune diseases, systemic sclerosis (3&middot;59 [2&middot;81&ndash;4&middot;59]), Addison's disease (2&middot;83 [1&middot;96&ndash;4&middot;09]), systemic lupus erythematosus (2&middot;82 [2&middot;38&ndash;3&middot;33]), and type 1 diabetes (2&middot;36 [2&middot;21&ndash;2&middot;52]) had the highest overall cardiovascular risk.</p> <p><strong>Interpretation:</strong>&nbsp;These findings warrant targeted cardiovascular prevention measures, in particular in younger patients with autoimmune diseases, and further research into pathophysiological mechanisms underlying these complications.</p> <p><strong>Funding:</strong>&nbsp;Horizon 2020 Marie Skłodowska-Curie Actions and European Society of Cardiology.</p>
spellingShingle Conrad, N
Verbeke, G
Molenberghs, G
Goetschalckx, L
Callender, T
Cambridge, G
Mason, JC
Rahimi, K
McMurray, JJV
Verbakel, JY
Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK
title Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK
title_full Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK
title_fullStr Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK
title_full_unstemmed Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK
title_short Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK
title_sort autoimmune diseases and cardiovascular risk a population based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the uk
work_keys_str_mv AT conradn autoimmunediseasesandcardiovascularriskapopulationbasedstudyon19autoimmunediseasesand12cardiovasculardiseasesin22millionindividualsintheuk
AT verbekeg autoimmunediseasesandcardiovascularriskapopulationbasedstudyon19autoimmunediseasesand12cardiovasculardiseasesin22millionindividualsintheuk
AT molenberghsg autoimmunediseasesandcardiovascularriskapopulationbasedstudyon19autoimmunediseasesand12cardiovasculardiseasesin22millionindividualsintheuk
AT goetschalckxl autoimmunediseasesandcardiovascularriskapopulationbasedstudyon19autoimmunediseasesand12cardiovasculardiseasesin22millionindividualsintheuk
AT callendert autoimmunediseasesandcardiovascularriskapopulationbasedstudyon19autoimmunediseasesand12cardiovasculardiseasesin22millionindividualsintheuk
AT cambridgeg autoimmunediseasesandcardiovascularriskapopulationbasedstudyon19autoimmunediseasesand12cardiovasculardiseasesin22millionindividualsintheuk
AT masonjc autoimmunediseasesandcardiovascularriskapopulationbasedstudyon19autoimmunediseasesand12cardiovasculardiseasesin22millionindividualsintheuk
AT rahimik autoimmunediseasesandcardiovascularriskapopulationbasedstudyon19autoimmunediseasesand12cardiovasculardiseasesin22millionindividualsintheuk
AT mcmurrayjjv autoimmunediseasesandcardiovascularriskapopulationbasedstudyon19autoimmunediseasesand12cardiovasculardiseasesin22millionindividualsintheuk
AT verbakeljy autoimmunediseasesandcardiovascularriskapopulationbasedstudyon19autoimmunediseasesand12cardiovasculardiseasesin22millionindividualsintheuk